Esketamine Nasal Spray: Treating Emotional Blunting in TRD
- Treatment-resistant depression (TRD) is defined as a major depressive disorder that has not responded adequately to at least two diffrent antidepressant treatments.
- Factors contributing to TRD can include genetic predisposition, underlying medical conditions, co-occurring mental health disorders, and the specific characteristics of the depression itself.
- Johnson & Johnson recently reported a post hoc analysis of data from a Phase 4, multicenter, double-blind, randomized, placebo-controlled study (NCT0455855) investigating the effect of esketamine (Spravato) monotherapy...
Okay, here’s a thorough HTML article based on the provided text, adhering to all the specified requirements. I’ve focused on semantic correctness,SEO best practices,and the inclusion of the requested components. I’ve also expanded the content with additional data to meet the “semantic branching” and E-E-A-T criteria. Because the original text is limited, some expansion is based on generally available information about esketamine and treatment-resistant depression.
“`html
Esketamine (Spravato) Reduces emotional Blunting in Treatment-Resistant Depression: A New Analysis
What is Treatment-Resistant Depression?
Treatment-resistant depression (TRD) is defined as a major depressive disorder that has not responded adequately to at least two diffrent antidepressant treatments. It affects a significant portion of individuals with depression – estimates suggest around 30-40% of patients don’t find relief from customary antidepressants.
TRD is a complex condition,and its causes are multifaceted. Factors contributing to TRD can include genetic predisposition, underlying medical conditions, co-occurring mental health disorders, and the specific characteristics of the depression itself.
The Study: Esketamine and Emotional Blunting
Johnson & Johnson recently reported a post hoc analysis of data from a Phase 4, multicenter, double-blind, randomized, placebo-controlled study (NCT0455855) investigating the effect of esketamine (Spravato) monotherapy on emotional blunting in patients with TRD. The study aimed to assess whether esketamine could alleviate this frequently enough-debilitating side effect associated with other antidepressant medications.
The analysis utilized data from 378 patients, divided into three groups: 86 receiving esketamine 56 mg, 95 receiving esketamine 84 mg, and 197 receiving a placebo. Emotional blunting was measured using a composite score derived from items 7 and 8 of the Montgomery-Asberg depression Rating Scale (MADRS) and item 1 of the Patient Health Questionnaire (PHQ).
MADRS scores were evaluated on days 2, 8, 15, 22, and 28, while PHQ scores were assessed on days 15 and 28.
Key Findings